Measles Market Trends And Growth Analysis By Type (Red Measles, German Measles), Treatment (Antibiotic, Antiviral, Vaccine (Mumps Measles Rubella, Varicella Virus, Live (Mmr-Ii) & Mumps Measles Rubella)), End User (Hospitals, Clinics, Other) - Global Forecast Till 2027
ID: MRFR/Pharma/3038-HCR | February 2021 | Region: Global | 80 pages
Market Synopsis of Global Measles Market Measles also referred as rubeola is a highly contagious disease caused by the rubeola virus. Measles is contracted through exposure to other individuals infected with the rubeola virus. Early symptoms of the disease are fever, red eyes, running nose, and cough. Furthermore, red spots and tiny rashes are observed on the skin of infected person. Measles is spread by a virus belonging to the paramyxovirus family and genus Morbillivirus. This virus first infects only the respiratory tract and then spreads throughout the body. Measles is predominantly a children’s disease, which has been controlled to a large extent today as compared to the past few decades. However, the disease still remains a matter of healthcare worry in most parts of the world. In developed nations, children are commonly provided with vaccination by the age of 18 months to immunize them against the disease. Measles vaccination is not recommended to be administered to a child before the completion of 18 months because an adequate quantity of immunoglobulin is already received via the placenta.
The global measles market is driven by increasing number of people with measles and increasing patients with immunosuppressant diseases. According to the report published by World Health Organization in 1980, measles caused an estimated 2.6 million deaths each year during the period. Additionally, in 2015, approximately 134000 people died globally due to measles. In same year, about 85% of world’s children received one dose of measles vaccine. Number of treatments are available for the measles such as antibiotic treatment, antiviral treatment, vaccine, and others. During the initial stages, the drug treatment is majorly administered. However, vaccines are considered as one of the most efficient ways to prevent the diseases. Patient suffering from immunosuppressant diseases are mostly affected by the disease. Increasing prevalence of autoimmune diseases, increasing need for the better treatment, rapid developments in technology and increasing government support for research & development have fuelled the growth of the market. However, high cost and limited availability of the treatment may slow the growth of the market over the assessment period.
The global measles market is expected to grow at a CAGR of ~ 5.1 % during the forecast period 2017-2023.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Industries
- Research and Development (R&D) Companies
- Hospitals and Clinics
- Academic Institutes and Universities
Figure: Global Measles Market by Treatment Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
Segments
The global measles market has been segmented on the basis of types, treatment, and end users.
On the basis of type, the market is segmented into red measles and German measles.
On the basis of treatment, the market is segmented into antibiotic treatment, antiviral treatment, vaccine and others. Vaccines are further segmented into mumps measles rubella vaccine, live (MMR-II) & mumps measles rubella, and varicella virus vaccine (Proquad).
On the basis of end user, the market is segmented into hospital, clinics, and others. Regional analysis The Americas dominates the global measles market owing to well-developed technology and increased patient population with measles. The World Health Organization (WHO) estimates that more than 30 million individuals are affected each year by measles worldwide with more than one million deaths. Vaccination has significantly reduced the number of cases in the United States, although isolated outbreaks continue to occur, and measles has been occurring more frequently in recent years due to an increased number of vaccine refusals. Additionally, increasing prevalence of the immunological diseases, high healthcare expenditure, and the presence of some of the leading players have fuelled the growth of the market in this region.
Europe is the second largest measles market, which is followed by Asia Pacific. Increasing government support and availability of funds for research drive the growth of the market. Asia Pacific is the fastest growing measles market due to a huge population base and rapidly developing medical sector.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities and poor economic and political conditions in Africa. However, African regions is expected to be the fastest growing market over the review period.
Key Players Some of key players profiled in the report are Abbott (US), Novartis AG (Switzerland), Biomedical diagnostics (US), Johnson & Johnson Services, Inc. (US), Sanofi (US), Merck & Co., Inc. (US), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), MedImmune (US Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (US), and GlaxoSmithKline plc (US), and others.
Research Methodology 
Sources: Annual reports, Press release, White paper, Company presentation
Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Measles Market, by Type
6.1 Introduction
6.2 Red Measles
Market Estimates & Forecast, 2020 – 2027
6.3 German Measles
Market Estimates & Forecast, 2020 – 2027
Chapter 7. Global Measles Market, by Treatment
7.1 Introduction
7.2 Antibiotic Treatment
Market Estimates & Forecast, 2020 – 2027
7.3 Antiviral Treatment
Market Estimates & Forecast, 2020 – 2027
7.4 Vaccine
Market Estimates & Forecast, 2020 – 2027
7.4.1 Mumps Measles Rubella Vaccine
7.4.2 Live (MMR-II) & Mumps Measles Rubella
7.4.3 Varicella Virus Vaccine
7.5 Others
Market Estimates & Forecast, 2020 – 2027
Chapter 8 Global Measles Market, by End User
8.1 Introduction
8.2 Hospitals
Market Estimates & Forecast, 2020 – 2027
8.3 Clinics
Market Estimates & Forecast, 2020 – 2027
8.4 Others
Chapter 9. Global Measles Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Novartis AG
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Abbott
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Biomedical diagnostics
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Johnson & Johnson Services, Inc.
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Sanofi
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Merck & Co., Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Serum Institute of India Pvt. Ltd.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Measles Industry Synopsis, 2020 – 2027
Table 2 Global Measles Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Measles Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Measles Market by Types, 2020 – 2027, (USD Million)
Table 5 Global Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 6 Global Measles Market by End Users, 2020 – 2027, (USD Million)
Table 7 North America Measles Market by Types, 2020 – 2027, (USD Million)
Table 8 North America Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 9 North America Measles Market by End Users, 2020 – 2027, (USD Million)
Table 10 US Market by Types, 2020 – 2027, (USD Million)
Table 11 US Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 12 US Measles Market by End Users, 2020 – 2027, (USD Million)
Table 13 Canada Market by Types, 2020 – 2027, (USD Million)
Table 14 Canada Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 15 Canada Measles Market by End Users, 2020 – 2027, (USD Million)
Table 10 South America Market by Types, 2020 – 2027, (USD Million)
Table 17 South America Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 18 South America Measles Market by End Users, 2020 – 2027, (USD Million)
Table 19 Europe Market by Types, 2020 – 2027, (USD Million)
Table 20 Europe Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 21 Europe Measles Market by End Users, 2020 – 2027, (USD Million)
Table 22 Western Europe Market by Types, 2020 – 2027, (USD Million)
Table 23 Western Europe Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 24 Western Europe Measles Market by End Users, 2020 – 2027, (USD Million)
Table 25 Eastern Europe Market by Types, 2020 – 2027, (USD Million)
Table 26 Eastern Europe Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Eastern Europe Measles Market by End Users, 2020 – 2027, (USD Million)
Table 28 Asia Pacific Market by Types, 2020 – 2027, (USD Million)
Table 29 Asia Pacific Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 30 Asia Pacific Measles Market by End Users, 2020 – 2027, (USD Million)
Table 31 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)
Table 32 Middle East & Africa Measles Market by Treatment, 2020 – 2027, (USD Million)
Table 33 Middle East & Africa Measles Market by End Users, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Measles Market
Figure 3 Segmentation Market Dynamics for Global Measles Market
Figure 4 Global Measles market Share, by type 2020
Figure 5 Global Measles market Share, by Treatment 2020
Figure 6 Global Measles Market Share, by End Users, 2020
Figure 7 Global Measles Market Share, by Region, 2020
Figure 8 North America Measles Market Share, by Country, 2020
Figure 9 Europe Measles Market Share, by Country, 2020
Figure 10 Asia Pacific Measles Market Share, by Country, 2020
Figure 11 Middle East & Africa Measles Market Share, by Country, 2020
Figure 12 Global Measles Market: Company Share Analysis, 2020 (%)
Figure 13 Novartis AG: Key Financials
Figure 14 Novartis AG: Segmental Revenue
Figure 15 Novartis AG: Geographical Revenue
Figure 16 Abbott: Key Financials
Figure 17 Abbott: Segmental Revenue
Figure 18 Abbott: Geographical Revenue
Figure 19 Biomedical diagnostics: Key Financials
Figure 20 Biomedical diagnostics: Segmental Revenue
Figure 21 Biomedical diagnostics: Geographical Revenue
Figure 22 Johnson & Johnson Services, Inc.: Key Financials
Figure 23 Johnson & Johnson Services, Inc.: Segmental Revenue
Figure 24 Johnson & Johnson Services, Inc.: Geographical Revenue
Figure 25 Sanofi: Key Financials
Figure 26 Sanofi: Segmental Revenue
Figure 27 Sanofi: Geographical Revenue
Figure 28 Merck & Co., Inc.: Key Financials
Figure 29 Merck & Co., Inc.: Segmental Revenue
Figure 30 Merck & Co., Inc.: Geographical Revenue
Figure 31 Serum Institute of India Pvt. Ltd.: Key Financials
Figure 32 Serum Institute of India Pvt. Ltd.: Segmental Revenue
Figure 33 Serum Institute of India Pvt. Ltd.: Geographical Revenue
